Executive Summary

The history of sulfonamides, or sulfa drugs, represents a pivotal chapter in pharmacology, illustrating how a single chemical scaffold, initially developed as an antibacterial, was serendipitously repurposed to create entire new classes of medications. This report provides an expert-level analysis of this transformative legacy, beginning with the dire medical landscape of the early 20th century and the discovery of Prontosil by Gerhard Domagk in 1932. The subsequent chemical revelation that the simpler sulfanilamide was the true active agent unleashed a wave of innovation, leading to the development of life-saving drugs for conditions far beyond their original purpose.

The sulfonamide functional group (SO2​NH2​) proved to be a versatile therapeutic core, enabling the creation of diuretics, antidiabetic agents, and treatments for inflammatory and neurological disorders. For instance, the accidental discovery of a diuretic side effect led to the development of carbonic anhydrase inhibitors and the groundbreaking thiazide and loop diuretics. Similarly, an observation of hypoglycemia during clinical trials for a new sulfa drug gave rise to the sulfonylurea class of oral antidiabetic agents. The report also examines the unique case of sulfasalazine, a prodrug whose mechanism of action, initially based on a flawed hypothesis, is now understood to involve a sophisticated modulation of the gut microbiome.

This narrative also explores the enduring clinical complexities associated with sulfonamides, particularly the issue of cross-reactivity and hypersensitivity reactions. While a common clinical practice, the broad caution against using non-antibiotic sulfonamides in patients with a sulfa allergy is found to be based on an incomplete understanding of their distinct metabolic pathways. The sulfonamide story is not merely a historical account but a testament to the unpredictable nature of scientific discovery, demonstrating how methodical research, coupled with keen observation and a willingness to challenge established dogma, can yield profound and lasting benefits for human health.

1. The Genesis of a “Miracle Drug”: A Historical and Chemical Foundation

The advent of sulfa drugs marks a revolutionary moment in medical history, fundamentally changing the prognosis for millions suffering from bacterial infections. This monumental shift is best understood by first examining the dire state of medicine in the early 20th century. Before the 1930s, the medical community possessed no effective treatments for common bacterial diseases, rendering infections like pneumonia, puerperal fever, and sepsis often fatal.¹ The period was defined by what have been termed “captains of death”—pathogens that could cause life-threatening septicemia from even the most minor wounds.³ A powerful and tragic example of this was the death of President Calvin Coolidge’s son in 1924, who succumbed to streptococcal septicemia after a minor blister.³ The grim reality of the time was so pronounced that women giving birth at home were often safer from puerperal fever than those attended by hospital staff, who were a vector for infection.³ The search for a solution to this pervasive problem was a critical medical imperative.

The eventual breakthrough came through the methodical and painstaking work of Gerhard Domagk, a German physician and researcher employed by the industrial conglomerate I.G. Farbenindustrie.¹ Between 1932 and 1935, Domagk and his team, including chemists Fritz Mietzsch and Josef Klarer, systematically tested thousands of chemical compounds, particularly those related to synthetic azo dyes.¹ Domagk’s hypothesis was that if these dyes could bind to the proteins in fabrics, they might similarly bind to bacterial proteins and inhibit their growth.¹ This rigorous five-year program culminated in a monumental discovery: Prontosil (sulfamidochrysoidine), the first sulfa drug, which demonstrated an “incredible antibacterial effect” against Streptococcus infections in laboratory mice.² The clinical efficacy of Prontosil was not just a theoretical finding from a laboratory experiment; it was confirmed in a deeply personal and dramatic way when Domagk’s own daughter, suffering from a severe, life-threatening infection from a knitting needle prick, was saved by the experimental drug.² Domagk published his findings in 1935 and was later awarded the 1939 Nobel Prize in Physiology or Medicine for his groundbreaking work.² The clinical impact was immediate and profound, with Prontosil playing a key role in reducing death rates from puerperal sepsis and saving the life of Franklin Delano Roosevelt Jr. in 1936.²

A critical turning point, however, occurred shortly after Prontosil’s introduction. While Domagk had patented the complete Prontosil molecule, French researchers made a pivotal discovery: when the drug was ingested, its molecules were cleaved in two, and the active antibacterial component was the much simpler, and crucially unpatented, sulfanilamide.¹ This revelation, made by an entirely different research group, was a foundational event that completely altered the trajectory of sulfonamide development. It liberated the intellectual property from a single patent and catalyzed a massive, decentralized research effort. With the core active moiety now in the public domain, scientists could freely create a vast range of new, structurally-related drugs. This led to the rapid proliferation of a whole new class of drugs, including sulfapyridine, sulfathiazole, and sulfadiazine, and paved the way for the exploration of new therapeutic applications beyond simple antibacterial action.¹ The origin story of sulfa drugs thus stands as a powerful demonstration of how targeted research can lead to an unexpected, second-order discovery that is far more impactful than the initial finding itself. Without the specific, and largely unforeseen, revelation that sulfanilamide was the active component, the sulfonamide story might have been confined to a single drug rather than becoming the basis for a diverse array of repurposed therapeutic classes.

2. The Pharmacological Pivot: The Sulfonamide Functional Group as a Therapeutic Core

The transformation of sulfonamides from a one-dimensional class of antibiotics into a diverse pharmacological toolkit is directly attributable to the versatility of a single chemical motif: the sulfonamide functional group, which has the general structure SO2​NH2​.⁶ The original antibacterial mechanism of sulfa drugs is a classic example of competitive inhibition at a target specific to bacteria. These drugs are bacteriostatic, meaning they inhibit bacterial growth rather than killing the bacteria outright.⁶ They achieve this by acting as a substrate analogue of p-aminobenzoic acid (PABA), a molecule essential for bacterial folate synthesis.⁸ By competitively inhibiting the enzyme dihydropteroate synthase, sulfonamides prevent bacteria from producing the folate they need for purine and DNA synthesis.⁶ This mechanism is highly specific and safe for humans because humans do not synthesize their own folate but instead acquire it from their diet, rendering their DNA synthesis largely unaffected.⁸

However, the enduring pharmacological legacy of the sulfonamide scaffold lies in its ability to be modified to interact with a variety of completely different biological targets. The chemical foundation of the sulfonamide group allows for the design of derivatives that retain some, all, or none of the original antibacterial properties while acquiring entirely new mechanisms of action. The genius of the repurposing narrative is that the same core structure that disrupts bacterial metabolism can, with subtle modifications, be harnessed to regulate fluid balance, control blood sugar, modulate inflammation, or calm neurological activity. This remarkable adaptability has led to the creation of several distinct and critically important classes of medications, as summarized in the table below.

Table 1: Key Sulfonamide Derivatives and Their Repurposed Applications

3. From Antimicrobial to Antihypertensive: The Development of Sulfa-Based Diuretics

The repurposing of sulfonamides as diuretics represents one of the most successful and impactful stories in pharmacological history. This began with a serendipitous observation during the initial clinical use of sulfanilamide. Researchers, including Robert Pitts at Cornell University and William Schwartz in Boston, found that the drug inhibited the enzyme carbonic anhydrase in the kidneys and caused patients to excrete large amounts of sodium and potassium in their urine.²³ This observation, initially a side effect, was recognized as being of “incredible importance” for the treatment of hypertension and edema, conditions for which the only alternative was the use of potentially toxic organomercurial diuretics.²³

This discovery led to the intentional development of a new class of drugs: carbonic anhydrase inhibitors (CAIs). The prototypical drug in this class, acetazolamide, was designed to exploit the newly discovered mechanism of action.¹⁰ The pharmacological principle behind CAIs is elegant. By inhibiting the carbonic anhydrase enzyme in the kidney’s proximal tubule, they prevent the reabsorption of bicarbonate ions.¹¹ This forces more bicarbonate and water to remain in the tubular lumen, leading to increased water excretion and a diuretic effect. The resulting alkalization of the urine is accompanied by a mild metabolic acidosis in the blood, which is beneficial for treating conditions like altitude sickness.¹¹ Beyond diuresis, this same mechanism of inhibiting carbonic anhydrase was found to be effective for treating glaucoma by reducing the production of aqueous humor, as well as for managing certain forms of epilepsy.¹⁰

Building on the CAI discovery, researchers at Merck Sharp and Dohme Research Laboratories, led by Karl H. Beyer, James M. Sprague, Frederick C. Novello, and John E. Baer, went on to develop a new compound, chlorothiazide, in the mid-1950s.²³ This compound heralded a new era of diuretic drugs known as thiazides.²³ These new drugs were a significant advancement as they could increase urine production effectively without disturbing the body’s electrolyte balance in the same way as earlier drugs.²³ The introduction of chlorothiazide in 1957 was an immediate commercial success, with 13 million prescriptions issued in its first year alone, making it a blockbuster drug for the treatment of congestive heart failure and high blood pressure.²³ The sulfonamide scaffold also served as the basis for the development of the even more potent loop diuretics, such as furosemide, bumetanide, and torsemide.⁶ These drugs act on a distinct target, inhibiting the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, a critical segment of the kidney’s filtration system.¹² This inhibition prevents the reabsorption of a significant portion of sodium and chloride, leading to a much more powerful diuretic effect than CAIs or thiazides.¹⁴

4. The Endocrine Connection: Sulfonylureas for Diabetes Management

The discovery of the hypoglycemic effects of sulfonamides is a captivating tale of both serendipity and geopolitical disruption. In the early 1940s, researchers in France, under the leadership of Marcel Janbon, were conducting clinical trials on a new sulfonamide compound (2254RP) for the treatment of typhoid.¹⁶ During these trials, a remarkable and completely unexpected side effect was observed: several of the emaciated patients experienced severe hypoglycemia, sometimes leading to fits or coma.¹⁶ This effect had not been seen with other sulfa drugs and prompted further investigation. The physiologist August Loubatières was able to confirm in animal studies that the drug caused a severe and progressive drop in blood glucose levels.²⁷ Crucially, he determined that this glucose-lowering effect was only present in animals with at least a small portion of their pancreas remaining, correctly inferring that the drug stimulated the release of insulin from the pancreatic islet cells.²⁷

This pivotal research, published largely in French, went largely unnoticed and its development was profoundly interrupted by the German occupation of France during World War II.¹⁶ The compounds were subsequently taken over by German pharmaceutical companies, which continued the research. However, this work, in turn, was halted by Germany’s defeat in 1945 and the subsequent partition of the country.¹⁶ For a period, the sulfonylureas were effectively “trapped” in East Germany, with their development stalled by the new political landscape.¹⁶ The continuation of this vital research was made possible only by the clandestine act of an individual who smuggled a drug sample to a West German pharmaceutical company in 1952.¹⁶ This singular, non-scientific event was a critical act of human agency that ensured the research’s survival and enabled the eventual development of the first commercially available sulfonylureas, tolbutamide and carbutamide, in 1956.¹⁶ The historical narrative of this class of drugs powerfully illustrates how scientific progress is not a linear march but is deeply intertwined with, and vulnerable to, the complex and unpredictable forces of human history and political strife. The fact that sulfonylureas are still considered essential and are on the World Health Organization’s List of Essential Medicines today is a testament to the resilience of the scientific community in overcoming such disruptions.²⁸

The mechanism of action for sulfonylureas involves a distinct pharmacological target from other sulfonamide derivatives. These compounds function as potassium channel blockers, a property that allows them to directly stimulate the secretion of insulin from the beta cells of the pancreas, thus lowering blood glucose levels.¹⁵ This discovery was revolutionary, as it offered the first effective oral treatment for type 2 diabetes, a condition that had previously been managed primarily with insulin injections.¹⁶ The initial generation of these drugs, including tolbutamide and carbutamide, laid the groundwork for the development of safer and more potent second- and third-generation sulfonylureas, such as glyburide, glipizide, and glimepiride.¹⁵ Despite the introduction of newer antidiabetic medications, sulfonylureas remain a cornerstone of diabetes treatment, particularly in resource-constrained settings, due to their proven efficacy in reducing A1c by 1-2 percent and their low cost.¹⁵

5. The Prodrug Principle: Sulfasalazine in Inflammatory Conditions

The development of sulfasalazine stands as a unique example of drug repurposing, rooted in a hypothesis that, while ultimately flawed, led to the creation of a highly effective therapeutic agent. Developed in the 1940s by Professor Nana Svartz in Stockholm, the drug was conceived to treat rheumatoid arthritis based on the then-prevailing but incorrect belief that the condition was caused by a bacterial infection.²⁹ The synthetic strategy was a clever one: to combine a known antibacterial sulfonamide, sulfapyridine, with an anti-inflammatory, 5-aminosalicylic acid (5-ASA, a derivative of salicylic acid), linking them via an azo bond.²⁹

The drug’s mechanism of action is a classic example of a prodrug, a compound that is inactive until it is metabolized within the body into its active components. Sulfasalazine is too large to be absorbed effectively in the small intestine, and consequently, over 90 percent of the orally administered dose reaches the large intestine intact.¹⁸ Once there, it encounters the anaerobic bacteria of the gut microbiome, which possess enzymes capable of reductively cleaving the azo bond.¹⁸ This process liberates the two constituent molecules: sulfapyridine and 5-ASA.¹⁸ The sulfapyridine moiety is subsequently absorbed into the systemic circulation and is responsible for most of the drug’s systemic side effects.¹⁸ Conversely, the 5-ASA component is poorly absorbed and is believed to act locally on the inflamed lining of the gut, which explains sulfasalazine’s efficacy in treating inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn’s disease.¹⁸

While this prodrug mechanism has been understood for some time, a more recent and profound discovery has reshaped the understanding of how sulfasalazine works. The efficacy of sulfasalazine in patients with IBD and an associated arthritis condition, spondyloarthritis (SpA), has been found to be directly linked to the presence of a specific gut bacterium, Faecalibacterium prausnitzii.¹⁷ The most recent research indicates that the drug’s therapeutic effect is not simply due to the release of 5-ASA but rather to its ability to specifically upregulate the production of butyrate by this particular bacterial species.¹⁷ Butyrate is a short-chain fatty acid known for its potent anti-inflammatory properties, and the drug’s effect is completely absent in animal models that lack the butyrate receptor on their cells, confirming the central role of this molecule.¹⁷ This evolving understanding of sulfasalazine’s action is a powerful case study in the dynamic nature of pharmacological knowledge. The drug was initially designed based on a flawed premise, its mechanism was later understood as a straightforward prodrug cleavage, and now, it is recognized as a sophisticated modulator of the host’s microbiota, effectively using gut bacteria as a bioreactor to produce a therapeutic compound. This progression from a simple, linear model to a complex, systems-level model of drug action is a crucial theme in modern pharmacology.

6. Diverse Applications: From Neurology to Dermatology

The remarkable adaptability of the sulfonamide scaffold extends to a range of other medical disciplines, showcasing its versatility far beyond the cardiovascular and endocrine systems.

In neurology, sulfonamide derivatives have found a significant role as anticonvulsants. A notable example is zonisamide, a chemically distinct sulfonamide derivative that was first used in Japan to treat psychiatric disorders before its widespread adoption for epilepsy.²⁰ Zonisamide’s antiepileptic properties stem from a unique dual mechanism of action: it blocks voltage-dependent sodium and T-type calcium channels, which are essential for controlling neuronal firing.²⁰ In addition to these primary actions, it also functions as a weak carbonic anhydrase inhibitor.¹⁹ The presence of a sulfamate moiety in other modern antiepileptic drugs like topiramate further underscores the therapeutic potential of this chemical structure in treating neurological disorders.¹⁹

Beyond systemic applications, sulfonamides have also been repurposed for effective topical treatments. Silver sulfadiazine, a combination of the sulfonamide sulfadiazine and silver, is a highly effective topical antibiotic widely used to prevent and treat infections in severe second- and third-degree burn wounds.²¹ The compound works by combining the antibacterial action of sulfadiazine with the potent antimicrobial effects of silver.²¹ This formulation creates a powerful barrier against bacterial growth, offering a critical layer of protection for patients with extensive skin damage.²¹

7. A Cautious Legacy: The Complex Issue of Sulfonamide Allergies

Despite their immense therapeutic value, sulfonamides are associated with a range of adverse effects, a significant number of which are hypersensitivity reactions. Common side effects can include headache, dizziness, diarrhea, and nausea, but the more severe reactions can be life-threatening.¹ These serious adverse events include hematologic reactions like agranulocytosis and hemolytic anemia, urinary tract disorders such as crystalluria, and severe cutaneous adverse reactions (SCARs) like Stevens-Johnson syndrome and toxic epidermal necrolysis.⁶

A pervasive and clinically significant issue stemming from these reactions is the widespread caution regarding a potential “sulfa allergy” and the fear of cross-reactivity between antibiotic and non-antibiotic sulfonamide-containing drugs. It has become common clinical practice to avoid prescribing non-antibiotic sulfonamides, such as diuretics and sulfonylureas, to patients with a documented history of allergy to sulfa antibiotics due to a “theoretical risk of cross-reactivity”.⁷

However, the scientific evidence for this cross-reactivity is sparse and not well documented.⁷ A deeper understanding of the chemical basis of sulfonamide hypersensitivity reveals a critical distinction that challenges this broad clinical dogma. Allergic reactions to antibacterial sulfonamides are primarily tied to the presence of an aromatic amine group at the N4 position of the molecule.⁶ The liver metabolizes this specific chemical group into reactive hydroxylamine metabolites, which can cause either direct cellular toxicity or an immune response.⁶ The vast majority of non-antibiotic sulfonamide derivatives, including carbonic anhydrase inhibitors, loop diuretics, and thiazides, lack this crucial aromatic amine group.⁷ Since their metabolic pathways are fundamentally different, the risk of a true allergic cross-reaction is minimal, if not negligible.³⁹ The persistence of this broad “sulfa allergy” label, despite mounting evidence to the contrary, can lead to the unnecessary withholding of effective and potentially life-saving medications from patients who could benefit from them.⁷ The issue is a powerful example of how outdated or incomplete scientific understanding can become ingrained in clinical practice, creating a barrier to optimal patient care.

8. Conclusion: The Enduring Impact of a Humble Dye

The history of sulfa drugs is a remarkable narrative of scientific innovation and accidental discovery. Starting with Gerhard Domagk’s methodical search for an antibacterial dye, the story was transformed by the pivotal discovery that the unpatented sulfanilamide moiety was the true active agent. This single chemical revelation democratized the research landscape and unleashed a wave of innovation that continues to this day. The sulfonamide functional group proved to be an extraordinarily versatile chemical scaffold, capable of being adapted to a wide array of biological targets.

From an antibacterial, the sulfonamide skeleton was repurposed to create the first effective oral diuretics, including the groundbreaking thiazides and loop diuretics. It led to the discovery of the sulfonylurea class of oral antidiabetic agents, which continue to be a cornerstone of diabetes management worldwide. The story of sulfasalazine demonstrates the power of the prodrug principle and the evolving understanding of how drugs can modulate the gut microbiome to produce therapeutic effects. Furthermore, the scaffold has given rise to important anticonvulsants and topical treatments for burn wounds.

The legacy of sulfonamides is not without its complexities, particularly regarding the issue of hypersensitivity reactions and the often-misguided fear of cross-reactivity. The scientific distinction between antibiotic and non-antibiotic sulfonamides is a critical one, and a better understanding of this nuance is essential for modern clinical practice. Ultimately, the story of sulfonamides is a timeless lesson in the power of observation, the dynamism of scientific knowledge, and the enduring human quest to turn unexpected discoveries into powerful tools for healing.

Works cited

1. Sulfonamide (medicine) | Research Starters – EBSCO, accessed September 13, 2025, https://www.ebsco.com/research-starters/health-and-medicine/sulfonamide-medicine
2. Domagk Discovers That Sulfonamides Can Save Lives | Research Starters – EBSCO, accessed September 13, 2025, https://www.ebsco.com/research-starters/history/domagk-discovers-sulfonamides-can-save-lives
3. Special Feature: Never say dye | British Columbia Medical Journal, accessed September 13, 2025, https://bcmj.org/newsnotes/special-feature-never-say-dye
4. Sulfonamides: far from obsolete | International Journal of Contemporary Pediatrics, accessed September 13, 2025, https://www.ijpediatrics.com/index.php/ijcp/article/view/2847
5. Prontosil – Wikipedia, accessed September 13, 2025, https://en.wikipedia.org/wiki/Prontosil
6. Sulfonamide (medicine) – Wikipedia, accessed September 13, 2025, https://en.wikipedia.org/wiki/Sulfonamide_(medicine)
7. Cross-Reactivity Between Sulfonamides and Loop or Thiazide Diuretics: Is it a Theoretical or Actual Risk? – PMC, accessed September 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3365608/
8. Sulfonamides – Infectious Diseases – Merck Manual Professional …, accessed September 13, 2025, https://www.merckmanuals.com/professional/infectious-diseases/bacteria-and-antibacterial-medications/sulfonamides
9. en.wikipedia.org, accessed September 13, 2025, https://en.wikipedia.org/wiki/Sulfanilamide#:~:text=As%20a%20sulfonamide%20antibiotic%2C%20sulfanilamide,%2Daminobenzoic%20acid%20(PABA).
10. Carbonic Anhydrase Inhibitors | DrugBank Online, accessed September 13, 2025, https://go.drugbank.com/categories/DBCAT000727
11. Carbonic Anhydrase Inhibitors – StatPearls – NCBI Bookshelf, accessed September 13, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557736/
12. Loop Diuretics PDF – Picmonic, accessed September 13, 2025, https://www.picmonic.com/api/v3/picmonics/1509/pdf
13. Loop Diuretics – StatPearls – NCBI Bookshelf, accessed September 13, 2025, https://www.ncbi.nlm.nih.gov/books/NBK546656/
14. Loop Diuretics Unique Mechanism of Action – JAPI, accessed September 13, 2025, https://japi.org/article/japi-72-9-s1-14
15. History of Popular Medications for Type 2 Diabetes | Beyond Type 1, accessed September 13, 2025, https://beyondtype1.org/history-medications-t2d/
16. Tolbutamide – Wikipedia, accessed September 13, 2025, https://en.wikipedia.org/wiki/Tolbutamide
17. New Insight into How an Old IBD Drug Works | Newsroom | Weill …, accessed September 13, 2025, https://news.weill.cornell.edu/news/2024/02/new-insight-into-how-an-old-ibd-drug-works
18. Sulfasalazine – StatPearls – NCBI Bookshelf, accessed September 13, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557809/
19. Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties – PubMed, accessed September 13, 2025, https://pubmed.ncbi.nlm.nih.gov/11784136/
20. Zonisamide – StatPearls – NCBI Bookshelf, accessed September 13, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507903/
21. Silver sulfadiazine (topical route) – Side effects & dosage – Mayo Clinic, accessed September 13, 2025, https://www.mayoclinic.org/drugs-supplements/silver-sulfadiazine-topical-route/description/drg-20068819
22. Silver Sulfadiazine Cream: Burn Treatment – Cleveland Clinic, accessed September 13, 2025, https://my.clevelandclinic.org/health/drugs/18830-silver-sulfadiazine-skin-cream
23. Developing diuretics – American Chemical Society, accessed September 13, 2025, https://pubsapp.acs.org/subscribe/archive/mdd/v06/i02/pdf/203timeline.pdf?
24. Discovery of Potent Carbonic Anhydrase and Acetylcholinesterase Inhibitors: 2-Aminoindan β-Lactam Derivatives – MDPI, accessed September 13, 2025, https://www.mdpi.com/1422-0067/17/10/1736
25. www.ncbi.nlm.nih.gov, accessed September 13, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557736/#:~:text=Carbonic%20anhydrase%20inhibitors%20are%20a,the%20diuretic%20class%20of%20medications.
26. Chlorothiazide – Wikipedia, accessed September 13, 2025, https://en.wikipedia.org/wiki/Chlorothiazide
27. Discovery of the sulphonylureas – DiabetesontheNet, accessed September 13, 2025, https://diabetesonthenet.com/diabetes-digest/discovery-of-the-sulphonylureas/
28. Sulfonylureas: Assets in the past, present and future – PMC, accessed September 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4366767/
29. SULPHASALAZINE IN THE TREATMENT OF RHEUMATOID ARTHRITIS, accessed September 13, 2025, https://academic.oup.com/rheumatology/article-pdf/36/3/382/18105186/360382.pdf
30. Sulfasalazine and its use in rheumatoid arthritis (RA) | NRAS, accessed September 13, 2025, https://nras.org.uk/resource/sulfasalazine/
31. Sulfasalazine and 5-Aminosalicylates (5-ASA) – IBD Journey …, accessed September 13, 2025, https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Treatment-and-Medications/Sulfasalazine-and-5-Aminosalicylates-5-ASA
32. Sulfasalazine | C18H14N4O5S | CID 5339 – PubChem, accessed September 13, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/5339
33. A polymeric drug for treatment of inflammatory bowel disease – PubMed, accessed September 13, 2025, https://pubmed.ncbi.nlm.nih.gov/6136612/
34. On the Action of 5-Amino-Salicylic Acid and Sulfapyridine on M. avium including Subspecies paratuberculosis | PLOS One – Research journals, accessed September 13, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000516
35. crohnsandcolitis.ca, accessed September 13, 2025, https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Treatment-and-Medications/Sulfasalazine-and-5-Aminosalicylates-5-ASA#:~:text=Resources-,What%20are%20sulfasalazine%20and%205%2DASAs%3F,the%20same%20in%20ulcerative%20colitis.
36. Sulphasalazine (DMARD) – Pharmacology, mechanism of action, metabolism, side effects, accessed September 13, 2025, https://www.youtube.com/watch?v=vzM4kidvu-Y
37. Zonisamide | Anti-Seizure Medication – Epilepsy Foundation, accessed September 13, 2025, https://www.epilepsy.com/tools-resources/seizure-medication-list/zonisamide
38. Sulfa allergy: Which medications should I avoid? – Mayo Clinic, accessed September 13, 2025, https://www.mayoclinic.org/diseases-conditions/drug-allergy/expert-answers/sulfa-allergy/faq-20057970
39. Which diuretics are safe and effective for patients with a sulfa allergy? – The Hospitalist, accessed September 13, 2025, https://blogs.the-hospitalist.org/content/which-diuretics-are-safe-and-effective-patients-sulfa-allergy